New Data Show Biodesix’s VeriStrat® Test is Cost-Saving, Improves Survival and Quality of Life in Advanced Lung-Cancer Patients
BOULDER, Colo., April 03, 2017 (GLOBE NEWSWIRE) -- Biodesix®, Inc. announced today new data demonstrating that use of the VeriStrat® test in patients with advanced non-small cell lung cancer (NSCLC) reduces the aggregate costs of end-of-life treatment …